相关实验视频
Updated: Jul 28, 2026

09:03
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
15.9K
微妙的混合拉波尼特-循环聚乙烯糖醇纳米颗粒作为潜在的药物输送系统
Shengzhuang Tang1, Jesse Chen1, Jayme Cannon1
1Michigan Nanotechnology Institute for Medicine and Biological Sciences and Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Pharmaceutics
|July 29, 2023
概括
这项研究引入了一种使用拉波尼特和循环聚乙烯甘醇 (cPEG) 纳米粒子的新型药物递送系统. 该LAP-cPEG/DOX配方显示出优异的多克索鲁比辛负载和受控释放,有效地抑制了肺癌细胞的增殖.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术纳米技术
- 生物医学工程 生物医学工程
背景情况:
- 开发先进的药物输送系统对于提高癌症治疗疗效和减少副作用至关重要.
- 拉波尼特 (LAP) 和聚乙烯糖醇 (PEG) 已被广泛用于基于纳米粒子的药物输送.
- 循环PEG (cPEG) 与线性PEG (mPEG) 相比,具有独特的结构性质.
研究的目的:
- 调查使用拉波尼特 (LAP) 和循环聚乙烯糖醇 (cPEG) 的新药物输送系统的可行性.
- 将LAP-cPEG/doxorubicin (DOX) 的药物加载效率和释放动力学与LAP-mPEG/DOX系统进行比较.
- 评估LAP-cPEG/DOX配方对A549肺癌细胞的体外疗效.
主要方法:
- 混合纳米晶体是通过对性和物理地将cPEG连接到拉波尼特纳米盘板来合成的.
- 在LAP-cPEG和LAP-mPEG配方中加载了 doxorubicin (DOX).
- 进行了药物加载效率,酸盐缓冲盐水 (PBS) 和人体血中的释放概况以及细胞活力测试.
主要成果:
- LAP-cPEG纳米晶体几乎是球形 (1-1.5微米),并且在装载DOX时是稳定的,与脆弱的LAP-mPEG板块不同.
- 在人体血中,LAP-cPEG/DOX系统表现出更高的药物加载效率和24小时的持续释放.
- 与LAP-mPEG/DOX相比,LAP-cPEG/DOX证明了对A549肺癌细胞增殖的增强抑制.
结论:
- LAP-cPEG混合纳米晶体系统为增强药物输送提供了一个有前途的平台.
- 控制释放和提高疗效表明有针对性的癌症治疗应用的潜力.
- 对于先进的药物向策略,对cPEG纳米粒子的进一步研究是有必要的.
相关概念视频
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

